ITGAE and neoplasm: This sustained‐release system improved tumor retention, boosted DC activation, and expanded memory T‐cell formation, amplifying systemic antitumor immunity.[23] In malignant pleural effusion (MPE), optimized intrapleural FOLactis delivery reduced pleural tumor burden and enhanced tumor‐specific immunity via activation of CD103+ DCs and effector T cells.[24] To overcome the limitations of personalized neoantigen peptide vaccines, we further developed Ag‐FOLactis using Plug‐and‐Display technology, enabling rapid neoantigen peptide presentation on the bacterial surface.